Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SinoMed, a Medical Device Company, Stages $50 Million IPO on the Shanghai STAR Exchange

publication date: Nov 4, 2019

Sino Medical Sciences completed an IPO on the Shanghai STAR Exchange last week, raising $50 million at a market capitalization of $412 million. The company makes high-end novel interventional medical devices for cardiovascular needs. Its products include drug eluting stents, balloon catheters, coronary stents and transcatheter mitral valve replacement kits. SinoMed's stock price rose as much as 217% in its first trading day. Founded in 2007, the company's headquarters and other operations, including R&D and production, are located in Tianjin. More details....

Stock Symbol: (SHA: 688108)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China